COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,629 Articles (22,913 medRxiv, 8,716 bioRxiv)

Most recent first Previous |  Page 963: Articles 9621-9630  | Next

A model of persistent post SARS-CoV-2 induced lung disease for target identification and testing of therapeutic strategies
Dinnon, K. H., Leist, S. R., Okuda, K., Dang, H., Fritch, E. J., Gully, K. L., Cruz, G., Evangelista, M. D., Asakura, T., Gilmore, R. C., Hawkins, P., Nakano, S., West, A., Schäfer, A., Gralinski, L. E., Everman, J. L., Sajuthi, S. P., Zweigart, M. R., Dong, S., McBride, J., Cooley, M. R., Hines, J. B., Love, M. K., Groshong, S. D., VanSchoiack, A., Phelan, S. J., Liang, Y., Hether, T., Leon, M., Zumwalt, R. E., Barton, L. M., Duval, E. J., Mukhopadhyay, S., Stroberg, E., Borczuk, A., Thorne, L. B., Sakthivel, M. K., Lee, Y. Z., Hagood, J. S., Mock, J. R., Seibold, M. A., O'Neal, W. K., Montgomery, S. A., Boucher, R. C., Baric, R. S.
10.1101/2022.02.15.480515 — Posted: 2022-02-15
A global lipid map reveals host dependency factors conserved across SARS-CoV-2 variants
Farley, S. E., Kyle, J., Leier, H., Bramer, L. M., Weinstein, J., Bates, T. A., Lee, J.-Y., Metz, T. O., Schultz, C., Tafesse, F.
10.1101/2022.02.14.480430 — Posted: 2022-02-15
A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions
Liu, Y., Zhang, X., Liu, J., Xia, H., Zou, J., Muruato, A. E., Periasamy, S., Plante, J. A., Bopp, N. E., Kurhade, C., Bukreyev, A., Ren, P., Wang, T., Menachery, V. D., Plante, K. S., Xie, X., Weaver, S. C., Shi, P.-Y.
10.1101/2022.02.14.480460 — Posted: 2022-02-15
Prior SARS-CoV2 infection in vaccinated solid organ transplant recipients induces potent neutralization responses against variants, including Omicron
Choudhary, A., Lerman, M., Calianese, D., Khan, S., Hunt, J., Nikaein, A., Honnen, W., Jaijyan, D. K., Kalu, E., Pinter, A.
10.1101/2022.02.10.22270607 — Posted: 2022-02-15
The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylatedIgG1 in naive but not antigen-experienced vaccinees
Van Coillie, J., Pongracz, T., Rahmoeller, J., Chen, H.-J., Geyer, C. E., van Vught, L. A., Buhre, J. S., Sustic, T., van Osch, T. L. J., Steenhuis, M., Hoepel, W., Wang, W., Lixenfeld, A., Nouta, J., Keijzer, S., Linty, F., Visser, R., Larsen, M. D., Martin, E. L., Kuensting, I., Lehrian, S., von Kopylow, V., Kern, C., Lunding, H., de Winther, M. P. J., van Mourik, N., Rispens, T., Graf, T., Slim, M. A., Minnaar, R. P., Bomers, M. K., Sikkens, J. J., Vlaar, A. P. J., van der Schoot, E. C., den Dunnen, J., Ehlers, M., Wuhrer, M., Vidarsson, G., Fatebenefratelli-Sacco Infectious Diseases Physicians group, , UMC COVID-19 S3/HCW study group
10.1101/2022.02.14.480353 — Posted: 2022-02-15
SARS-CoV-2 Omicron-specific mRNA vaccine induces potent and broad antibody responses in vivo
Fang, Z., Peng, L., Lin, Q., Ren, P., Suzuki, K., Xiong, Q., Clark, P., Lin, C., Chen, S.
10.1101/2022.02.14.480449 — Posted: 2022-02-15
Virological characteristics of SARS-CoV-2 BA.2 variant
Yamasoba, D., Kimura, I., Nasser, H., Morioka, Y., Nao, N., Ito, J., Uriu, K., Tsuda, M., Zahradnik, J., Shirakawa, K., Suzuki, R., Kishimoto, M., Kosugi, Y., Kobiyama, K., Hara, T., Toyoda, M., Tanaka, Y. L., Butlertanaka, E. P., Shimizu, R., Ito, H., Wang, L., Oda, Y., Orba, Y., Sasaki, M., Nagata, K., Yoshimatsu, K., Asakura, H., Nagashima, M., Sadamasu, K., Yoshimura, K., Kuramochi, J., Seki, M., Fujiki, R., Kaneda, A., Shimada, T., Nakada, T.-a., Sakao, S., Suzuki, T., Ueno, T., Takaori-Kondo, A., Ishii, K. J., Schreiber, G., The Genotype to Phenotype Japan (G2P-Japan) Consortium, , Sawa, H., Saito, A., Irie, T., Tanaka, S., Matsuno, K., Fukuhara, T., Ikeda, T., Sato, K.
10.1101/2022.02.14.480335 — Posted: 2022-02-15
A novel consensus-based computational pipeline for rapid screening of antibody therapeutics for efficacy against SARS-CoV-2 variants of concern including omicron variant
Kumar, N., Kaushik, R., Zhang, K. Y. J., Uversky, V. N., Srivastava, P., Sahu, U., Sood, R., Bhatia, S.
10.1101/2022.02.11.480177 — Posted: 2022-02-15
SARS-CoV-2-specific T cells associate with reduced lung function and inflammation in pulmonary post-acute sequalae of SARS-CoV-2
Littlefield, K., Watson, R., Schneider, J., Neff, C., Yamada, E., Zhang, M., Campbell, T., Falta, M., Jolley, S., Fontenot, A., Palmer, B.
10.1101/2022.02.14.480317 — Posted: 2022-02-15
Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose
Muecksch, F., Wang, Z., Cho, A., Gaebler, C., Ben Tanfous, T., DaSilva, J., Bednarski, E., Ramos, V., Zong, S., Johnson, B., Raspe, R., Schaefer-Babajew, D., Shimeliovich, I., Daga, M., Yao, K.-H., Schmidt, F., Millard, K. G., Turroja, M., Jankovic, M., Oliveira, T. Y., Gazumyan, A., Caskey, M., Hatziioannou, T., Bieniasz, P. D., Nussenzweig, M.
10.1101/2022.02.14.480394 — Posted: 2022-02-15

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).